AVMXF

Avita Medical (PK) Stock Price

0.55
0.00 (0.0%)
0.55
Best deals to access real time data!
Small Cap Basic
Monthly Subscription
for only
$33.03
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Avita Medical Ltd (PK) AVMXF OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.55 20:00:00
Close Price Low Price High Price Open Price Previous Close
0.55 0.55
Bid Price Ask Price Spread News
1.00 10.00 9.00 - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.55 USD

Avita Medical (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.03B 1.87B - $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
2.71M $ - 0.00% - -

more financials information »

Avita Medical (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AVMXF Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.30490.6750.2310.32569433,8160.245180.39%
1 Year0.4010.6750.1730.3858431266,7940.14937.16%
3 Years0.050.6750.0020.3103077283,5600.501,000.0%
5 Years0.05950.6750.0020.2950489209,1490.4905824.37%

Avita Medical (PK) Description

Avita Medical Limited is a regenerative medicine company with a technology platform designed to address unmet medical needs in patients with burns, chronic wounds, and aesthetics indications. The Company's patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient's own skin. The Company's medical devices work by preparing a Regenerative Epidermal Suspension (RES), an autologous suspension comprised of the patient's own skin cells that are necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment. The first medical device based on the RES technology, the RECELL System, was approved for sale in the U.S. for the treatment of acute thermal burns by the Food and Drug Administration (FDA) in September 2018. The Company initiated its U.S. national market launch of the RECELL System in January 2019. The RECELL System is also sold on a limited basis in certain regions of the world in which the products are approved for sale, including Australia, China and Europe.


Your Recent History
USOTC
AVMXF
Avita Medi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.